Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten Boers

Showing results (291-300 of 308) with videos related to

Pageof 31
Sort By:
Seminars in Arthritis and Rheumatism|April 20, 2021
OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods studySabrina Mai Nielsen, Maarten Boers, Maarten de Wit, et al.
The Journal of Rheumatology|March 18, 2014
Updating the OMERACT filter: core areas as a basis for defining core outcome setsJohn R Kirwan, Maarten Boers, Sarah Hewlett, et al.
The Journal of Rheumatology|March 4, 2014
Updating the OMERACT filter: implications for imaging and soluble biomarkersMaria-Antonietta D'Agostino, Maarten Boers, John Kirwan, et al.
The Journal of Rheumatology|January 17, 2019
The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee OsteoarthritisToby O Smith, Gillian A Hawker, David J Hunter, et al.
The Journal of Rheumatology|March 3, 2019
Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017Toby O Smith, Michael Mansfield, Gillian A Hawker, et al.
The Journal of Rheumatology|October 6, 2005
Minimal disease activity for rheumatoid arthritis: a preliminary definitionGeorge A Wells, Maarten Boers, Beverley Shea, et al.
Annals of the Rheumatic Diseases|October 29, 2013
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Seminars in Arthritis and Rheumatism|June 27, 2026
Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinementDorthe B Berthelsen, Ben Horgan, Lee Simon, et al.
Annals of the Rheumatic Diseases|May 8, 2010
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitisNeil Basu, Richard Watts, Ingeborg Bajema, et al.
Allergy|August 1, 2012
Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meetingJochen Schmitt, Phyllis Spuls, Maarten Boers, et al.
Pageof 31

Showing results (291-300 of 308) with videos related to

Sort By:
Pageof 31
Seminars in Arthritis and Rheumatism|April 20, 2021
OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods studySabrina Mai Nielsen, Maarten Boers, Maarten de Wit, et al.
The Journal of Rheumatology|March 18, 2014
Updating the OMERACT filter: core areas as a basis for defining core outcome setsJohn R Kirwan, Maarten Boers, Sarah Hewlett, et al.
The Journal of Rheumatology|March 4, 2014
Updating the OMERACT filter: implications for imaging and soluble biomarkersMaria-Antonietta D'Agostino, Maarten Boers, John Kirwan, et al.
The Journal of Rheumatology|January 17, 2019
The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee OsteoarthritisToby O Smith, Gillian A Hawker, David J Hunter, et al.
The Journal of Rheumatology|March 3, 2019
Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017Toby O Smith, Michael Mansfield, Gillian A Hawker, et al.
The Journal of Rheumatology|October 6, 2005
Minimal disease activity for rheumatoid arthritis: a preliminary definitionGeorge A Wells, Maarten Boers, Beverley Shea, et al.
Annals of the Rheumatic Diseases|October 29, 2013
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Seminars in Arthritis and Rheumatism|June 27, 2026
Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinementDorthe B Berthelsen, Ben Horgan, Lee Simon, et al.
Annals of the Rheumatic Diseases|May 8, 2010
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitisNeil Basu, Richard Watts, Ingeborg Bajema, et al.
Allergy|August 1, 2012
Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meetingJochen Schmitt, Phyllis Spuls, Maarten Boers, et al.
Pageof 31